SSRI (Selective Serotonin Reuptake Inhibitor)
Pregnancy: Use if benefit outweighs risk. Long half-life means neonatal exposure after stopping.
Fluoxetine
Brand names: Prozac
Adult dose
Dose: 20 mg once daily; increase to 40–60 mg if needed
Route: Oral
Frequency: Once daily (morning — activating effect)
Max: 60 mg/day (80 mg/day for bulimia)
Depression: 20 mg OD, increase to 40–60 mg after 4 weeks if poor response. Bulimia nervosa: 60 mg/day. OCD: 20 mg initially, increase to 40–60 mg/day. Due to long half-life (1–4 days + active metabolite), can be given alternate days in elderly. Fewer discontinuation effects than other SSRIs.
Paediatric dose
Route: Oral
Frequency: Once daily
Max: 20 mg/day (child); 40 mg/day (adolescent)
Licensed for moderate-severe depression and OCD (8–17 years): 10 mg OD initially (8–17 years); after 1–2 weeks, increase to 20 mg OD. Adolescents with greater body weight: may need 20 mg/day initially. Max 20 mg/day (children); 40 mg/day (adolescents).
Dose adjustments
Renal
No dose adjustment required for mild-moderate impairment; consider dose reduction in severe renal failure.
Hepatic
Reduce dose or use alternate-day dosing in severe hepatic impairment.
Clinical pearls
- Longest half-life SSRI — fewer discontinuation effects; once-weekly dosing possible in stable patients
- Avoid in breast cancer patients on tamoxifen (CYP2D6 inhibition reduces active tamoxifen metabolite)
- Preferred SSRI for eating disorders (particularly bulimia nervosa)
- Licensed for depression and OCD in children in UK (only SSRI with UK paediatric licence)
- 5-week washout before starting MAOI (long half-life)
Contraindications
- MAO inhibitors within 14 days
- Pimozide or thioridazine
- Linezolid or IV methylene blue
Side effects
- Nausea and GI upset (usually transient)
- Insomnia (activating — take in morning)
- Anxiety and agitation
- Sexual dysfunction
- Weight loss initially then possible weight gain
- Hyponatraemia (SIADH)
- Suicidal ideation (young patients)
Interactions
- MAOIs — serotonin syndrome; 5-week washout required after fluoxetine before starting MAOI
- Tamoxifen — significantly reduced efficacy (potent CYP2D6 inhibitor — use sertraline instead)
- Tricyclic antidepressants — increased TCA levels
- Warfarin — increased bleeding risk
- Atomoxetine — increased levels (risk of toxicity)
Monitoring
- Mood and suicidality
- Weight
- Serum sodium (elderly)
- Drug interactions (CYP2D6 inhibitor)
Reference: BNFc; BNF; NICE CG90; BNFc. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Drugs
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF